Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

20.70
Delayed Data
As of Jan 19
 0.00 / 0.00%
Today’s Change
10.85
Today|||52-Week Range
37.94
+9.23%
Year-to-Date
Generic-Drug Stocks Are Looking Sickly
Jan 18 / TheStreet.com - Paid Partner Content
Parkinson's Disease Space Again Under Spotlight This Week
Jan 11 / Zacks.com - Paid Partner Content
Opioids Get Their Day In Washington, but Effort To Dump Medicaid Gets Spotlight
Jan 17 / TheStreet.com - Paid Partner Content
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
Jan 11 / Zacks.com - Paid Partner Content
Horan Securities, Inc. Buys Teva Pharmaceutical Industries, Pattern Energy Group Inc,...
Jan 16 / GuruFocus News - Paid Partner Content
Momenta Reports Positive Top-Line Data on Antibody M281
Jan 09 / Zacks.com - Paid Partner Content
Teva's Trisenox Gets FDA Approval as First-Line Treatment
Jan 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close20.70
Today’s open20.78
Day’s range20.14 - 21.25
Volume21,428,408
Average volume (3 months)26,247,925
Market cap$21.0B
Data as of 4:04pm ET, 01/19/2018

Growth & Valuation

Earnings growth (last year)-96.18%
Earnings growth (this year)-25.31%
Earnings growth (next 5 years)-1.95%
Revenue growth (last year)+12.01%
P/E ratioNM
Price/Sales1.59
Price/Book0.71

Competitors

 Today’s
change
Today’s
% change
BGNEBeiGene Ltd0.000.00%
TYMETyme Technologies In...0.000.00%
OASMOasmia Pharmaceutica...0.000.00%
Data as of 4:00pm ET, 01/19/2018

Financials

Next reporting dateFebruary 8, 2018
EPS forecast (this quarter)$0.77
Annual revenue (last year)$22.0B
Annual profit (last year)$330.0M
Net profit margin1.50%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
Kåre Schultz
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Hamerkaz

Forecasts